Related Experiment Videos
Complete Remission in Systemic Skin Interdigitating Dendritic Cell Sarcoma after ABVD Chemotherapy
Chieko Kyogoku1, Masanori Seki, Shinichi Ogawa
1Department of Hematology, Faculty of Medicine, University of Tsukuba.
Insights
Interdigitating dendritic cell sarcoma (IDCS) is a rare cancer. ABVD chemotherapy achieved complete remission in a patient with extensive skin lesions, suggesting its potential efficacy for this aggressive neoplasm.
Area of Science:
- Oncology
- Hematology
- Dermatopathology
Background:
- Interdigitating dendritic cell sarcoma (IDCS) is a rare, aggressive neoplasm originating from dendritic cells.
- Typically affects lymph nodes, but can involve extranodal sites, including skin and bone marrow.
Observation:
- A 62-year-old male presented with multiple skin nodules on the head, body, and extremities, along with bone marrow involvement.
- Histopathological and immunohistochemical analysis confirmed the diagnosis of IDCS, with tumor cells positive for CD4, CD45, CD68, and S-100 protein.
Findings:
- The patient achieved complete remission after 6 cycles of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.
- Tumor cells exhibited characteristic IDCS-associated antigen expression.
Implications:
- This case suggests ABVD chemotherapy may be an effective treatment for IDCS, particularly in patients with extensive cutaneous involvement.
- Further research is warranted to establish optimal treatment protocols for this rare malignancy.
Abstract:
Interdigitating dendritic cell sarcoma (IDCS) is a rare and aggressive neoplasm that is thought to arise from dendritic cells. This disease usually involves the lymph nodes and, rarely, extra-nodal sites. We report a 62-year-old man presenting skin nodules in the head, body, and extremities, as well as bone marrow involvement. Morphologic analysis of a biopsied specimen from the skin lesion was consistent with IDCS. Immunohistochemical staining demonstrated that the tumor cells were positive for IDCS-associated antigens such as CD4, CD45, CD68 (KP-1), and S-100 protein. Complete remission was achieved by treatment with 6 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) chemotherapy. Although the optimal treatment of IDSC remains unknown, the experience in the current case supports the notion that ABVD chemotherapy may be effective for IDCS, and further extends this idea to rare patients presenting multiple skin lesions.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...